25
Views
3
CrossRef citations to date
0
Altmetric
The John Pratt-Johnson Annual Lecture

A Case Report: Consecutive Cranial Neuropathies Following the Use of Phosphodiesterase-5 Inhibitors

, M.D. & , M.D., Ph.D.
Pages 109-114 | Published online: 22 Dec 2017

References

  • Duan XG: Tadalafil for erectile dysfunction: An overview. Zhonghua Nan Ke Xue (National Journal of Andrology) 2013; 19: 380–383.
  • Dersch R, Anastasopoulos C, Hader C, Stich O: Vertebral artery dissection associated with sildenafil abuse. J Clin Neurosci 2013; 20: 742.
  • Stefanovic-Budimkic M, Jovanovic DR, Beslac-Bumbasirevic L, Ercegovac MD: Recurrent ischemic stroke associated with sildenafil and tadalafil use in a young adult. Clin Neurol Neurosurg 2012; 114: 405–407.
  • Bae EK, Ahn JH, Park JJ: Nonaneurysmal subarachnoid hemorrhage after udenafil intake. J Stroke Cerebrovasc Dis 2013; 22: e647–649.
  • Galvez-Ruiz A, Arishi N: Sequential, non-arteritic anterior ischemic optic neuropathy in patients taking sildenafil: A report often cases. Saudi J Ophthalmol 2013; 27: 241–246.
  • Tatli E, Cakar MA, Dogan E, Alkan M: Does sildenafil contribute to acute coronary thrombosis? Turk Kardiyol Dern Ars 2012; 40: 536–539.
  • Bertolucci A, Latkany RA, Gentile RC, Rosen RB: Hemi-retinal artery occlusion associated with sexual activity and sildenafil citrate (Viagra). Acta Ophthalmol Scand 2003; 81: 198–200.
  • Marmor MF, Kessler R: Sildenafil (Viagra) and ophthalmology. Surv Ophthalmol 1999; 44: 153–162.
  • Center for Drug Evaluation and Research: Phase I investigator-blind, placebo-controlled, evaluation of safety, toleration and pharmacokinetics of sildenafil following escalating single oral doses in healthy male volunteers: Study 148–004. In: Viagra (sildenafil): Joint Clinical Review for NDA-20–895. Center for Drug Evaluation and Research. Food and Drug Administration: Washington; 1998, pp. 96–98.
  • Donahue SP, Taylor RJ: Pupil-sparing third nerve palsy associated with sildenafil citrate (Viagra). Am J Ophthalmol 1998; 126: 476–477.
  • Mas M: Molecular mechanisms of penile erection. Archivos Espanoles de Urologia 2010; 63: 589–598.
  • Cockrill BA, Waxman AB: Phosphodiesterase-5 inhibitors. Handb Exp Pharmacol 2013; 218: 229–255.
  • Gur S, et al.: PDE-5 inhibitor treatment options for urologic and non-urologic indications: 2012 update. Curr Pharm Des 2012; 18: 5590–5606.
  • Mittleman MA, Carrier S, Seftel AD: Cardiovascular outcomes among sildenafil users: Results of the International Men's Health Study: Cardiovascular outcomes among sildenafil users: Results of the International Men's Health Study M.A. Mittleman, M. Maclure, M.A. Lewis, G.C. Hall, N. Moore, F. Giuliano, H. Porst, H. Hedelin, A. Martin-Morales, R.E. Sobel, R. Reynolds, and D.B. Glasser. J Sex Med; 11: 880–884.
  • Bertero E, Montorsi F: Safety of sildenafil citrate: Review of 67 double-blind placebo-controlled trials and the postmarketing safety database: F. Giuliano, G. Jackson, F. Montorsi, A. Martin-Morales, and P. Raillard. J Sex Med 2014; 11: 885–887.
  • Nielsen JR, et al.: Effects of imipramine of the orthostatic changes in blood pressure, heart rate, and plasma catecholamines. Clin Exp Pharmacol Physiol 1983; 10: 497–504.
  • Dopp JM, et al.: Sildenafil increases sympathetically mediated vascular tone in humans. Am J Hypertens 2013; 26: 762–769.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.